The prospect of FDA obtaining a combined bill reauthorizing existing user fee programs and creating two others could be challenging, given that some negotiations have yet to begin and agreements may not be completed fast enough to meet congressional time tables.

The prospect of FDA obtaining a combined bill reauthorizing existing user fee programs and creating two others could be challenging, given that some negotiations have yet to begin and agreements may not be completed fast enough to meet congressional time tables.

The Generic Pharmaceutical Association is pretty fond of Florida. The group has held its annual meeting in the state almost every year since the association was formed. But regardless of the weather or the hotel amenities, when GPhA convenes in Orlando next month, its members will be slightly disappointed in the venue: Florida is below the national average in the generic utilization rate for its Medicaid program.